Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Millennium | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Financial Report: Millennium

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Millennium 

4Q Revenues: $181.2 million (+30%)

4Q Earnings: $41.0 million (earnings were $8.3 million in 4Q2006)

FY Revenues: $527.5 million (+8%)

FY Earnings: $14.9 million (loss of $44.0 million FY2006)

Comments: U.S. sales of Velcade were $265.2 million, up 20% for the year, and royalties were $166.9 million, up 24% due to growth in Velcade sales outside of the U.S., which were more than $500 million. This growth led to achievement of a non-recurring $40 million milestone from Ortho Biotech Products. FY results include a $17.0 million decrease in stock-based compensation expense and a $7.5 million decrease in restructuring charges. 4Q and FY R&D expenses were $76.4 million (-6%) and $287.1 million (-8%).
 

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters